Inherent Group’s Cano Health, Inc. CANO Stock Holding History

Inherent Group’s Portfolio CANO Stock Details CANO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,000	Closed	-$891K	–	56
2021 Q4	$891K	Buy	+1,000	New	+$1.05M	0.15%	45

Other funds holding CANO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Third Point New York $2.08B AUM 27.04% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

OCAM

Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Inherent Group's CANO Position: Q1 2022 in Review

Inherent Group sold out of Cano Health, Inc. (CANO) in Q1 2022, closing a stake of 7,035 shares — an estimated $6.27M sold.

Inherent Group first reported a position in CANO in Q1 2021 and held it in 4 quarters. The position peaked at $21.5M in Q3 2021. 146 funds tracked by Wall St. Rank hold CANO as of Q1 2022.

Inherent Group reported no remaining Cano Health, Inc. position as of Q1 2022 after selling out during the quarter.
Inherent Group sold 7,035 Cano Health, Inc. shares in Q1 2022, an estimated $6.27M.
Inherent Group first reported a position in Cano Health, Inc. in Q1 2021 and held it in 4 quarters.
Inherent Group's Cano Health, Inc. position peaked at $21.5M in Q3 2021.
146 funds tracked by Wall St. Rank held Cano Health, Inc. as of Q1 2022.

Based on Inherent Group's 13F filing for Q1 2022, filed 16 May 2022.